Flurbiprofen in the treatment of ankylosing spondylitis: A comparison with indomethacin

doi:10.1016/0002-9343(86)90129-4

The American Journal of Medicine

Volume 80, Issue 3, Supplement 1, 24 March 1986, Pages 127-132

https://doi.org/10.1016/0002-9343(86)90129-4 Get rights and content

Abstract

In this randomized, double-blind study, 57 patients with ankylosing spondylitis were evaluated after 26 weeks of treatment with either flurbiprofen (Ansaid, Upjohn) or indomethacin. Flurbiprofen administered four times a day in a total daily dose of 200 mg was effective in controlling the pain and associated symptoms of ankylosing spondylitis. Pain was adequately controlled in some patients following a total daily dose of 100 mg of flurbiprofen administered twice a day. Flurbiprofen was as effective as indomethacin in most key efficacy measurements analyzed. The drug was well tolerated in doses of up to 300 mg per day, and no clinically significant laboratory abnormalities were detected. Flurbiprofen is an excellent treatment for the control of pain and inflammation in patients with ankylosing spondylitis.

References (4)

RD Sturrock et al.
Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis
Ann Rheum Dis
(1974)
A Calin et al.
Double-blind cross-over trial of flurbiprofen and phenylbutazone in ankylosing spondylitis
Brit Med J
(1974)

There are more references available in the full text version of this article.

Cited by (10)

Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinion
2007, Joint Bone Spine
Citation Excerpt :
The extent of agreement among experts regarding this recommendation was 98.4%. Of 35 randomized controlled trials that investigated the efficacy of NSAIDs in AS, 32 compared NSAIDs and 6 also included a placebo group [7,9,11–40]. None of these studies found any evidence indicating that a specific NSAID was superior over the others.
To develop recommendations about pharmacotherapy (excluding biotherapeutic agents) in patients with axial forms of ankylosing spondylitis (AS) seen in everyday clinical practice.
The recommendations were based on evidence from the literature. First, a scientific committee used a Delphi procedure to select five focal points about which recommendations were needed. Then, a literature task force looked for relevant publications in the following: Cochrane, PubMed, and Ovid databases; and abstracts from the French Society for Rheumatology, European League against Rheumatism, and American College of Rheumatology. Based on the data in these publications, recommendations were drafted then validated by a group of experts. The strength of each recommendation was determined, as well as the extent of agreement among the experts.
The four focal points were the best strategy for using nonsteroidal anti-inflammatory drugs, role for systemic glucocorticoid therapy, role for glucocorticoid injections into the sacroiliac joints and entheses, and role for slow-acting drugs (e.g., methotrexate, sulfasalazine, leflunomide, thalidomide, and pamidronate). Of the 661 promising publications identified by the literature search, 173 were found to be relevant. The evidence in these 173 papers was reported to experts during interactive workshops. At the end of the workshops, the experts drafted recommendations, which were then validated by having all panel participants vote during a final meeting. There were seven recommendations, whose strength ranged from A to D.
Seven recommendations about pharmacotherapy in patients with AS were developed. They can be expected to improve clinical practice uniformity and, in the longer term, to optimize the management of patients with AS in France.
Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis
2021, Advances in Rheumatology
Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)
2015, Cochrane Database of Systematic Reviews
Single dose oral flurbiprofen for acute postoperative pain in adults
2009, Cochrane Database of Systematic Reviews
Single dose oral flurbiprofen for acute postoperative pain in adults
2008, Cochrane Database of Systematic Reviews
Update of NSAID treatment in spondyloarthritis
2007, Reumatologia Clinica

View all citing articles on Scopus

^☆: The work presented was based on the administration of Ansaid tablets, a registered trademark of The Upjohn Company.

View full text

Flurbiprofen in the treatment of ankylosing spondylitis: A comparison with indomethacin☆

Abstract

Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis

Ann Rheum Dis

Double-blind cross-over trial of flurbiprofen and phenylbutazone in ankylosing spondylitis

Brit Med J